Thyroid Eye Disease Market Current Trends Analysis 2026 to 2035
Global Thyroid Eye Disease Market Size is valued at USD 2.26 billion in 2024 and is predicted to reach USD 4.02 billion by the year 2034 at a 6.0% CAGR during the forecast period for 2025 to 2034.
Thyroid Eye Disease Market Size, Share & Trends Analysis Report By Marketed Treatment (TEPEZZA (Teprotumumab), By Pipeline Treatment (VRDN 001, VB 421, Batoclimab, Linsitnib), By Region, And By Segment Forecasts, 2026 to 2035

Thyroid Eye Disease is an autoimmune condition that causes eye swelling, bulging, and pain, often linked to Graves' disease. Treatments include Tepezza, corticosteroids, and surgery to reduce symptoms like eye bulging and vision problems.
Improved healthcare settings, improvements in autoimmune disease treatment, and positive patient compliance percentage are factors expected to drive the growth of the global Thyroid Eye Disease market. Increasing research & development activities and rising investment are some of the other factors expected to augment the target market growth. The increasing adoption of artificial tears and lubricating eye drops to alleviate dryness and give temporary relief from discomfort globally is expected to boost the market expansion in the coming years.
However, the high cost of Thyroid Eye Disease and lack of a clear thyroid eye treatment, coupled with the COVID-19 outbreak, are factors that may limit growth of the target market during the forecast period. Furthermore, increasing R&D activities, government actions to use sustainable components for production, investments by prominent players are factors expected to create lucrative growth opportunities in terms of revenue for players operating in the global Thyroid Eye Disease market over the forecast period.
Competitive Landscape
Some Major Key Players In The Thyroid Eye Disease Market:
- Horizon Therapeutics
- Viridian Therapeutics
- Pierre Fabre/ACELYRIN
- HanAll Biopharma/Harbour BioMed/Immunovant
- Sling Therapeutics
- Other Market Players
Market Segmentation:
The Thyroid Eye Disease market is segmented on the basis of marketed treatment and pipeline treatment. Based on the marketed treatment, the market is segmented as tepezza (Teprotumumab). By pipeline treatment, the market is segmented into VRDN 001, VB 421, batoclimab, and linsitinib.
Based On Marketed Treatment, The TEPEZZA (Teprotumumab) Segment Is Accounted As A Major Contributor In The Thyroid Eye Disease Market.
The TEPEZZA (Teprotumumab) category is expected to hold a major share of the global Thyroid Eye Disease market in 2023. This is attributed to help in reducing eye bulges and double vision. Additionally, it also decreases the signs and symptoms of thyroid eye disease, including eye pain, edema, and eye disease.
VRDN-001 Segment Witnessed Growth At A Rapid Rate
The VRDN-001 segment is projected to grow at a rapid rate in the global Thyroid Eye Disease market owing to growing use in treating several fatal diseases. The VRDN-001 is an intravenous monoclonal antibody that goals the anti-insulin-like growth factor-1 receptor. The major benefit of using VRDN-001 in treating these diseases is that they are taken from a biological source.
In The Region, The North America Thyroid Eye Disease Market Holds A Significant Revenue Share.
The North America Thyroid Eye Disease market is expected to report the most increased market share in terms of revenue. This can be attributed to the strong focus on the treatment of thyroid eye disease in the region. In addition, the growing prevalence of several thyroid diseases and advancement in treatment options for Thyroid Eye Disease is also expected to increase the growth of the target market. Growing healthcare setups and rising research and development activities in the region are factors increasing the growth of the target market in the region. In addition, the region Asia Pacific is projected to grow rapidly in the global Thyroid Eye Disease market due to growing concerns about thyroid eye disease, increasing healthcare expenditure, government initiatives, and increasing funding in various industries.
Recent Developments:
- In March 2024, ACELYRIN, INC. announced positive proof-of-concept results from a Phase ½ trial of lonigutamab in thyroid eye condition that is now underway. Lonigutamab is a subcutaneous (SC) humanized IgG1 monoclonal antibody that aims the insulin-like growth factor-1 receptor (IGF-1R), a known mechanism of action for thyroid eye disease treatment.
Thyroid Eye Disease Market Report Scope :
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 2.26 Bn |
| Revenue Forecast In 2034 | USD 4.02 Bn |
| Growth Rate CAGR | CAGR of 6.0% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Marketed Products, Pipeline treatment |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
| Competitive Landscape | Horizon Therapeutics, Viridian Therapeutics, Pierre Fabre/ACELYRIN, HanAll Biopharma/Harbour BioMed/Immunovant, and Sling Therapeutics. |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Thyroid Eye Disease Market L
Thyroid Eye Disease Market By Marketed Products-
- TEPEZZA (Teprotumumab)
Thyroid Eye Disease Market By Pipeline Treatment-
- VRDN-001
- VB421
- Batoclimab
- Linsitinib)
Thyroid Eye Disease Market By Region-
- North America-
- The US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
- Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Afric
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Thyroid Eye Disease Market Size is valued at USD 2.26 billion in 2024 and is predicted to reach USD 4.02 billion by the year 2034
The Thyroid Eye Disease Market is expected to grow at a 6.0% CAGR during the forecast period for 2025-2034.
Horizon Therapeutics, Viridian Therapeutics, Pierre Fabre/ACELYRIN, HanAll Biopharma/Harbour BioMed/Immunovant, and Sling Therapeutics.
Marketed Products, Pipeline treatment are the key segments of the Thyroid Eye Disease Market.
North American region is leading the Thyroid Eye Disease Market.